Oral antiplatelet therapy for acute ischaemic stroke

Peter A G Sandercock, Carl Counsell, Mei-Chiun Tseng, Emanuela Cecconi

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

In people with acute ischaemic stroke, platelets become activated and can cause blood clots to form and block an artery in the brain, resulting in damage to part of the brain. Such damage gives rise to the symptoms of stroke. Antiplatelet therapy might reduce the volume of brain damaged by ischaemia and also reduce the risk of early recurrent ischaemic stroke, thereby reducing the risk of early death and improving long-term outcomes in survivors. However, antiplatelet therapy might also increase the risk of fatal or disabling intracranial haemorrhage.
Original languageEnglish
Article numberCD000029
JournalCochrane Database of Systematic Reviews
Issue number3
DOIs
Publication statusPublished - 26 Mar 2014

Fingerprint

Stroke
Intracranial Hemorrhages
Brain
Brain Ischemia
Thrombosis
Therapeutics
Blood Platelets
Arteries

Cite this

Oral antiplatelet therapy for acute ischaemic stroke. / Sandercock, Peter A G; Counsell, Carl; Tseng, Mei-Chiun; Cecconi, Emanuela.

In: Cochrane Database of Systematic Reviews, No. 3, CD000029, 26.03.2014.

Research output: Contribution to journalArticle

Sandercock, Peter A G ; Counsell, Carl ; Tseng, Mei-Chiun ; Cecconi, Emanuela. / Oral antiplatelet therapy for acute ischaemic stroke. In: Cochrane Database of Systematic Reviews. 2014 ; No. 3.
@article{7f97357e90ff4f49bd750ef56947490f,
title = "Oral antiplatelet therapy for acute ischaemic stroke",
abstract = "In people with acute ischaemic stroke, platelets become activated and can cause blood clots to form and block an artery in the brain, resulting in damage to part of the brain. Such damage gives rise to the symptoms of stroke. Antiplatelet therapy might reduce the volume of brain damaged by ischaemia and also reduce the risk of early recurrent ischaemic stroke, thereby reducing the risk of early death and improving long-term outcomes in survivors. However, antiplatelet therapy might also increase the risk of fatal or disabling intracranial haemorrhage.",
author = "Sandercock, {Peter A G} and Carl Counsell and Mei-Chiun Tseng and Emanuela Cecconi",
year = "2014",
month = "3",
day = "26",
doi = "10.1002/14651858.CD000029.pub3",
language = "English",
journal = "Cochrane Database of Systematic Reviews",
issn = "1469-493X",
publisher = "Wiley",
number = "3",

}

TY - JOUR

T1 - Oral antiplatelet therapy for acute ischaemic stroke

AU - Sandercock, Peter A G

AU - Counsell, Carl

AU - Tseng, Mei-Chiun

AU - Cecconi, Emanuela

PY - 2014/3/26

Y1 - 2014/3/26

N2 - In people with acute ischaemic stroke, platelets become activated and can cause blood clots to form and block an artery in the brain, resulting in damage to part of the brain. Such damage gives rise to the symptoms of stroke. Antiplatelet therapy might reduce the volume of brain damaged by ischaemia and also reduce the risk of early recurrent ischaemic stroke, thereby reducing the risk of early death and improving long-term outcomes in survivors. However, antiplatelet therapy might also increase the risk of fatal or disabling intracranial haemorrhage.

AB - In people with acute ischaemic stroke, platelets become activated and can cause blood clots to form and block an artery in the brain, resulting in damage to part of the brain. Such damage gives rise to the symptoms of stroke. Antiplatelet therapy might reduce the volume of brain damaged by ischaemia and also reduce the risk of early recurrent ischaemic stroke, thereby reducing the risk of early death and improving long-term outcomes in survivors. However, antiplatelet therapy might also increase the risk of fatal or disabling intracranial haemorrhage.

U2 - 10.1002/14651858.CD000029.pub3

DO - 10.1002/14651858.CD000029.pub3

M3 - Article

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 3

M1 - CD000029

ER -